March 18, 2026
11 11 11 AM
Brody Jenner Defends Kylie Jenner & Timothée Chalamet Relationship
Total repression and air strikes bring unrelenting dread for Iranians
Why Carole Radziwill Isn’t Featured in Love Story
Trump seeks to delay meeting with Xi in China
Sink Your Teeth Into Robert Pattinson & Suki Waterhouse’s Oscars Date
Iran taking steps to prevent anti-establishment protests, Tehran residents tell BBC
Prince William Shares Unseen Photo of Princess Diana in Sweet Tribute
US names six crew killed in refuelling plane crash in Iraq
Stila Founder Shares Her Hack for Makeup That Lasts All Night
Under drone fire, exiled Kurds wait to confront Iranian regime
Latest Post
Brody Jenner Defends Kylie Jenner & Timothée Chalamet Relationship Total repression and air strikes bring unrelenting dread for Iranians Why Carole Radziwill Isn’t Featured in Love Story Trump seeks to delay meeting with Xi in China Sink Your Teeth Into Robert Pattinson & Suki Waterhouse’s Oscars Date Iran taking steps to prevent anti-establishment protests, Tehran residents tell BBC Prince William Shares Unseen Photo of Princess Diana in Sweet Tribute US names six crew killed in refuelling plane crash in Iraq Stila Founder Shares Her Hack for Makeup That Lasts All Night Under drone fire, exiled Kurds wait to confront Iranian regime

Intranasal vaccine against H5 avian flu provokes broad immune response in adults in phase 1 trial

Three of five groups of eight participants each received low, medium, or high doses of the clade 2.1 influenza A/H5 (A/Indonesia/05/2005) recombinant hemagglutinin glycoprotein (rH5) vaccine combined with an adjuvant; one group received 100 µg of an unadjuvanted rH5 vaccine; and one group received placebo. All participants received an intramuscular H5 booster 6 months later.

Participants who received the adjuvanted vaccine had higher levels of protective antibodies (immunoglobulin [Ig] G and A), more memory immune cells, and a better ability to neutralize infected cells.

Only recipients of the boosted intranasal vaccine showed strong immune priming. Even without a booster, the intranasal vaccine triggered mucosal and systemic immunity, which other intranasal recombinant H5 flu vaccines have not achieved in clinical trials. It also was safe and well-tolerated.

The immune system’s ability to recognize multiple strains of H5N1 virus is key because they change over time, co-lead author Meagan Deming, MD, PhD, said in a university news release. “The use of the adjuvant also suggests this approach might allow for lower doses of the vaccine, which could make our current vaccine stocks available to more people in the event of an outbreak,” she said.

Corresponding author Justin Ortiz, MD, said that global transmission of H5N1 in animals, including spillover into people, underscores the need for effective countermeasures. “This trial shows that this intranasal, shelf-stable H5N1 vaccine could play a major role in pandemic preparedness, offering a practical and scalable way to help protect people from evolving strains of the virus,” he said.

11 thoughts on “Intranasal vaccine against H5 avian flu provokes broad immune response in adults in phase 1 trial

  1. Your blog is a testament to your dedication to your craft. Your commitment to excellence is evident in every aspect of your writing. Thank you for being such a positive influence in the online community.

  2. I just wanted to drop by and say how much I appreciate your blog. Your writing style is both engaging and informative, making it a pleasure to read. Looking forward to your future posts!

  3. Hello Neat post Theres an issue together with your site in internet explorer would check this IE still is the marketplace chief and a large element of other folks will leave out your magnificent writing due to this problem

  4. Your blog is a testament to your dedication to your craft. Your commitment to excellence is evident in every aspect of your writing. Thank you for being such a positive influence in the online community.

Leave a Reply

Your email address will not be published. Required fields are marked *